HLTH vs Hospitalar for Exhibitors
Side-by-side data and our editorial take on which conference is the right exhibit investment for your medical device.
If you exhibit medical devices, HLTH and Hospitalar are likely both on your shortlist. Both serve overlapping clinical buyers, but the audience composition, booth economics, and exhibit floor experience differ in ways that materially affect ROI. HLTH draws 12,000 attendees with an estimated all-in 10×10 of TBD. Hospitalar draws 91,000 attendees at TBD all-in. Below is the side-by-side data plus our editorial take on which conference fits which kind of exhibitor.
| 9.3 HLTH | 9.5 Hospitalar | |
|---|---|---|
| Score | ||
| Buzzbox Score | 9.3 (Exceptional) | 9.5 (Exceptional) |
| Event Details | ||
| Dates | November 15-18, 2026 | May 19-22, 2026 |
| Location | The Venetian Expo & Convention Center, Las Vegas, NV | Sao Paulo Expo Exhibition & Convention Center, Sao Paulo, Brazil |
| Scale | mega | mega |
| Audience | ||
| Attendees | 12,000 | 91,000 |
| Exhibitors | — | — |
| Purchasing authority | ~50% | ~55% |
| Effective buyers | 6,000 | 50,050 |
| Costs | ||
| $/sqft | — | — |
| 10×10 space | — | — |
| All-in estimate | — | — |
| Cost per buyer | — | — |
Why exhibit at HLTH
The dominant US healthcare innovation conference with 12,000+ senior decision-makers, investors, and digital health executives. Turnkey booths with AV included reduce logistical burden. If you are a digital health, AI, or health IT company seeking enterprise health system or payer customers, this is where deals start.
Why exhibit at Hospitalar
The #1 gateway to Latin America's healthcare markets. Brazil alone is the 6th largest medical device market globally. 91,000+ attendees with significant government procurement officers make this essential for companies expanding into LatAm.
Why skip HLTH
Extremely expensive -- minimum booth is 10x20 (no 10x10 option), and turnkey pricing with no publicly listed rates suggests $30k+ entry point. Heavily skewed toward digital health and payer innovation, not traditional medical devices. Clinician presence is minimal compared to clinical conferences.
Why skip Hospitalar
Brazil's ANVISA regulatory pathway is complex and slow. Companies without existing Brazilian registration or a local importer/distributor will collect leads they can't convert for 12-24 months. Portuguese-language materials are essential -- English-only booths underperform badly.